Aspira Women’s Health, a company highlighted on diagnostic technologies, has announced some big changes in its leadership team. The President, Dr. Sandra Milligan, will be leaving the company for personal reasons on February 21, 2025. After she leaves, Jamie Sullivan and Todd Pappas will take over her duties.
Ellen Beausang has been appointed as a new member of the Board of Directors. She has over 25 years of experience in the pharmaceutical and diagnostic industry, having worked at big companies like Pfizer, Thermo Fisher, and Quest Diagnostics. Her experience in marketing and product development is expected to be helpful to Aspira. The company reported revenue of $8.96 million in the past year, with a profit margin of 58.12%. Beausang has been serving as President-Chief Commercial Officer at BioReference Health since June 2022.
These changes are happening as Aspira Women’s Health focuses on improving its women’s health diagnostic tests. The company is based in Austin, Texas, and is incorporated under Delaware laws.
Aspira Women’s Health has made several leadership changes recently. They appointed Michael Buhle as CEO and James Crawford as VP of Finance, with Dr. Sandra Milligan continuing as President. This followed the resignation of Interim CFO John Kallassy. Additionally, Aspira is facing the possibility of being removed from the Nasdaq Capital Market because they don’t meet the minimum market value requirement.
Despite these challenges, Aspira reported a 2% increase in revenue for their OvaSuite tests in the third quarter of 2024, with test volume growing by 4%. The company also received a $10 million federal award to develop a test for endometriosis called ENDOinform. Aspira is focused on expanding its ovarian cancer test offerings and improving its commercial capabilities.
These recent changes highlight the dynamic nature of Aspira Women’s Health and their commitment to advancing women’s health diagnostics.